SEHK:6990Biotechs
Does Breakthrough Status For Sacituzumab Tirumotecan-Keytruda Combo Reshape Kelun-Biotech’s Oncology Strategy (SEHK:6990)?
Sichuan Kelun-Biotech Biopharmaceutical recently announced that its TROP2-directed ADC sacituzumab tirumotecan, combined with MSD’s KEYTRUDA, received Breakthrough Therapy Designation in China for first-line treatment of certain advanced non-small cell lung cancer patients, while its CEO highlighted pipeline progress and globalisation plans at the J.P. Morgan Healthcare Conference.
The clustering of multiple Breakthrough Therapy Designations around sacituzumab tirumotecan, alongside...